(+)-N-3-benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: New potent and selective in vitro inhibitors of CYP2C19

Drug Metabolism and Disposition

Volumn 30, Issue 3, 2002, Pages 235-239

  Suzuki, Hisashi ^a   Byron Kneller, M ^a   Haining, Robert L ^a,b   Trager, William F ^a   Rettie, Allan E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; FLUORESCEIN DERIVATIVE; MEPHENYTOIN; N 3 BENZYLNIRVANOL; N 3 BENZYLPHENOBARBITAL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; MALE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; ENZYME INHIBITORS; FEMALE; FLUOROMETRY; HUMANS; HYDROXYLATION; ISOENZYMES; MALE; MEPHENYTOIN; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; PHENOBARBITAL; STEREOISOMERISM; SUBSTRATE SPECIFICITY;

EID: 0036179579     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.3.235     Document Type: Article

References (30)

1. Role of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite
2. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
3. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes
4. Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6
5. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes
6. Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms
7. m diazepam. N-demethylases
8. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: Potent effect on CYP2C19 and CYP2D6
9. Role of CYP2C19 in stereoselective hydroxylation of mephobarbital by human liver microsomes
10. The effects of selective serotonin reuptake inhibitors and their metabolisms on S-mephenytoin 4′-hydroxylase activity in human liver microsomes
11. Metabolism of the immunosuppressant tacrolimus in the small intestine: Cytochrome P450, drug interactions, and interindividual variability
12. Inhibition and induction of cytochrome P450 and the clinical implications
13. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature
14. Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes
15. Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes
16. Inhibition and induction of human cytochrome P450 (CYP) enzymes
17. Characteristics of warfarin hydroxylation catalyzed by human liver microsomes
18. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily
19. Relationship between mephenytoin oxidation polymorphism and phenytoin, methylphenytoin and phenobarbitone hydroxylation assessed in a phenotyped panel of healthy subjects
20. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450
21. Hydantoin and barbiturate inhibitors of CYP2C19 and CYP2C9
22. Metabolically-based drug-drug interactions: Principles and mechanisms
23. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor
24. Escitalopram (s-citalopram) and its metabolites in vitro: Cytochromes mediating biotransformation, inhibitory effects, and comparison to r-citalopram
25. The CYP2C19 enzyme polymorphism
26. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery
27. Formation of (R)-8-hydroxywarfarin in human liver microsomes: A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19
28. The human hepatic cytochromes P450 involved in drug metabolism
29. Clomipramine N-demethylation metabolism in human liver microsomes
30. Evaluation of methoxsalen, tranylcypromine and tryptamine as specific and selective CYP2A6 inhibitors in vitro